Paul R. Sanberg - Böcker

Prominent experimentalists critically review the animal models widely used in developing powerful new therapies for central nervous system diseases. Coverage includes novel uses of animal models of Alzheimer's, Parkinson's, and Huntington's diseases, and studies of aging. Techniques that rely heavily on behavioral analyses, as well as models developed from infusions of neurotoxins and from advances in molecular biology, are thoroughly explicated, as are models developed for more acute neurological conditions, including traumatic brain injury and stroke. Comprehensive and authoritative, Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic offers neuroscientists, pharmacologists, and interested clinicians a unique survey of the most productive animal models of the leading neurological diseases currently employed to develop today's innovative drug therapies.

Respected investigators from around the world critically review what is known about the role of mitochondrial inhibitors in cell death and the onset of neurodegeneration. These distinguished researchers - many pioneers in the field - detail the symptomology, origin, and chemistry of mitochondrial toxins, and discuss animal models of human diseases related to abnormal mitochondrial function. The emphasis on 3-NP and its ability to replicate the cellular, anatomical, and behavioral alterations seen in Huntington's disease demonstrate that mitochondrial inhibitors play an important role in the etiology of central nervous system disorders. The book also discusses recent therapeutic modalities aimed at rescuing the central nervous system from abnormal mitochodrial functioning. With its timely, in-depth review, Mitochondrial Inhibitors and Neurodegenerative Disorders offers today's advanced investigators powerful insights into how mitochondrial toxins precipitate and exacerbate neurodegenerative disorders, and details important new treatment strategies that can halt or reverse disease progression.

An authoritative survey of the most recent scientific evidence showing how cyclosporin, FK-506, and their analogs-the neuroimmunophilins-evolved from being purely immunosuppressant "drugs" to neuroprotective "agents". The book focuses on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. It also discusses their efficacy and mechanisms of action in vitro and in vivo models of CNS disease, and provides laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction.

An authoritative survey of the most recent scientific evidence showing how cyclosporin, FK-506, and their analogs-the neuroimmunophilins-evolved from being purely immunosuppressant "drugs" to neuroprotective "agents". The book focuses on recent preclinical evidence that demonstrates the neurotrophic/neuroprotective effects of immunosuppressants when administered alone or when combined with neural transplantation therapy in animal models of neurological disorders. It also discusses their efficacy and mechanisms of action in vitro and in vivo models of CNS disease, and provides laboratory studies with compelling clinical indications for Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, spinal cord injury, ALS, sciatic nerve injury, and drug addiction.

Believed to be the remnants of bacterial infection of eukaryotic cells eons ago, the mitochondrion evolved a symbiotic relationship in which it dutifully served as the efficient source of A TP for cell function.

As our world continues to evolve, the field of regenerative medicine f- lows suit. Although many modern day therapies focus on synthetic and na- ral medicinal treatments for brain repair, many of these treatments and prescriptions lack adequate results or only have the ability to slow the p- gression of neurological disease or injury. Cell therapy, however, remains the most compelling treatment for neurodegenerative diseases, disorders, and injuries, including Parkinson’s disease, Huntington’s disease, traumatic brain injury, and stroke, which is expanded upon in more detail in Chapter 1 by Snyder and colleagues. Cell therapy is also unique in that it is the only therapeutic strategy that strives to replace lost, damaged, or dysfunctional cells with healthy ones. This repair and replacement may be due to an administration of exogenous cells itself or the activation of the body’s own endogenous reparative cells by a trophic, immune, or inflammatory response to cell transplantation. However, the precise mechanism of how cell therapy works remains elusive and is c- tinuing to be investigated in terms of molecular and cellular responses, in particular. Moreover, Chapter 11 by Emerich and associates, discusses some of the possibilities of cell immunoisolation and the potential for treating central nervous system diseases.

Prominent experimentalists critically review the animal models widely used in developing powerful new therapies for central nervous system diseases. Coverage includes novel uses of animal models of Alzheimer's, Parkinson's, and Huntington's diseases, and studies of aging. Techniques that rely heavily on behavioral analyses, as well as models developed from infusions of neurotoxins and from advances in molecular biology, are thoroughly explicated, as are models developed for more acute neurological conditions, including traumatic brain injury and stroke. Comprehensive and authoritative, Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic offers neuroscientists, pharmacologists, and interested clinicians a unique survey of the most productive animal models of the leading neurological diseases currently employed to develop today's innovative drug therapies.